Core Viewpoint - Q32 Bio's shares plummeted nearly 77% following mixed results from two Phase IIa studies for its drug bempikibart, leading to a decision to focus on alopecia areata while discontinuing eczema development [1][2][3] Group 1: Study Results - The alopecia areata study showed a 16% mean reduction in the Severity of Alopecia Tool (SALT) score for patients treated with bempikibart, compared to a 2% reduction in the placebo group [5] - In the eczema study, 76% of placebo recipients showed improvement versus 74% in the bempikibart group, indicating a lack of efficacy for the drug in this indication [7][8] - Management plans to enroll around 20 additional patients for a Part B expansion of the alopecia areata study due to unforeseen participant dropouts [6] Group 2: Stock Performance - Following the announcement, Q32 Bio's stock hit an all-time low of $5.80, reflecting investor concerns about the drug's efficacy [3] - Year-to-date, Q32 Bio's shares have declined by 45.6%, contrasting with an 8.7% decline in the industry [3]
Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday